Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity [see comments]
AIDS. 1998 Sep 10;12(13):1675-82. Unique Identifier : AIDSLINE MED/98435817 Wilkinson D; Floyd K; Gilks CF; Centre for Epidemiological Research in Southern Africa, Medical; Research Council, Mtubatuba.
Abstract:
OBJECTIVE: To estimate cost-effectiveness and capacity requirements for providing antiretroviral drugs to pregnant HIV-infected women in rural South Africa. SETTING: Hlabisa health district, where HIV prevalence among pregnant women was 26.0% in 1997. METHODS: Calculation of the number of paediatric HIV infections averted under three scenarios, and their cost. No intervention was compared with scenario A (zidovudine delivered within current infrastructure), scenario B (zidovudine delivered through enhanced infrastructure), and scenario C (short-course zidovudine plus lamivudine delivered through enhanced infrastructure). Cost-effectiveness was defined as cost per infection averted and cost per potential life-year gained. Capacity was determined in terms of staff and infrastructure required to effectively implement the scenarios. RESULTS: With no intervention, 657 paediatric HIV infections were projected for 1997. In scenario A this could be reduced by 15% at a cost of US$ 574 825, in scenario B by 42% at US$ 1520770, and in scenario C by 47% at US$ 764901. In scenario C, drugs accounted for 76% of costs, whereas additional staff accounted for 18%. Cost per infection averted was US$ 2492 and cost per potential life-year gained (discounted at 3%) was US$ 88. Cost of scenario C was equivalent to 14% of the 1997 district health budget. At least 12 extra counsellors and nurses and one laboratory technician, together with substantial logistical and managerial support, would be needed to deliver an effective intervention. CONCLUSION: Although antiretrovirals may be relatively cost-effective in this setting, the budget required is currently unaffordable. Developing the capacity required to deliver the intervention would pose both a major challenge, and an opportunity, to improve health services.
Keywords: JOURNAL ARTICLE Adult Anti-HIV Agents/*ECONOMICS/*THERAPEUTIC USE Cost-Benefit Analysis Female Human HIV Infections/*DRUG THERAPY HIV Seroprevalence Intervention Studies Pregnancy Pregnancy Complications, Infectious/*DRUG THERAPY Public Health Practice/*ECONOMICS *Rural Health South Africa Zidovudine/ECONOMICS/THERAPEUTIC USE Comment in: AIDS 1998 Sep 10;12(13):1571-80
990228
A9920961
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
